- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- Fact Check
- Bone Health Fact Check
- Brain Health Fact Check
- Cancer Related Fact Check
- Child Care Fact Check
- Dental and oral health fact check
- Diabetes and metabolic health fact check
- Diet and Nutrition Fact Check
- Eye and ENT Care Fact Check
- Fitness fact check
- Gut health fact check
- Heart health fact check
- Kidney health fact check
- Medical education fact check
- Men's health fact check
- Respiratory fact check
- Skin and hair care fact check
- Vaccine and Immunization fact check
- Women's health fact check
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Corticosteroids use in IBD Patients may increase COVID-19 complication
Individuals with inflammatory bowel disease (IBD) under corticosteroids are at elevated risk for severe COVID-19 complications. The findings were published in Inflammatory Bowel Diseases.
The retrospective cohort study, spanning from August 2019 to August 2021, enrolled a substantial 102,986 patients with IBD (48,728 with Crohn's disease and 47,592 with ulcerative colitis), with an average age of 53, of which 55% were female. The research delved into the utilization of various IBD medications in the 90 days preceding cohort entry, tracking patient outcomes through COVID-19 hospitalization, mechanical ventilation or inpatient death.
Preliminary findings indicate that 0.4% of the IBD patients (412 individuals) required hospitalization due to COVID-19. Notably, patients using corticosteroids exhibited a higher incidence of hospitalization (0.6% compared to 0.3% in non-users).
This trend translated to an increased likelihood of needing mechanical ventilation for corticosteroid users (1.9% compared to 0.05% in non-users), with a similar pattern observed in inpatient deaths due to COVID-19. In contrast, patients receiving anti-tumor necrosis factor α therapy showcased a lower rate of hospitalization (0.2% compared to 0.5% in non-users), suggesting a potential protective effect.
Age also emerged as a significant factor impacting COVID-19 outcomes, with older patients experiencing higher hospitalization rates. The study's aggregate data nature precluded more advanced multivariate analyses, leaving room for future research to explore these relationships in greater depth.
These findings carry important implications for clinical practice. The study underscores the higher COVID-19 risk associated with corticosteroid use in IBD patients, advocating for careful consideration of the benefits and risks of such treatment, particularly in the context of the ongoing pandemic. On the other hand, the potential protective effect of anti-tumor necrosis factor α therapy provides clinicians with valuable insights into treatment decisions for IBD patients during the pandemic.
As the medical community continually refines its understanding of COVID-19 and its interactions with various patient populations and treatments, studies like this provide a critical foundation for evidence-based decision-making.
Reference:
Long, M. D., Parlett, L., Lewis, J. D., Haynes, K., Adimadhyam, S., Hou, L., Wolfe, A., Toh, S., Burris, J., Dorand, J., & Kappelman, M. D. (2023). Corticosteroids but not Anti-TNF Are Associated With Increased COVID-19 Complications in Patients With Inflammatory Bowel Disease. In Inflammatory Bowel Diseases. Oxford University Press (OUP). https://doi.org/10.1093/ibd/izad176
Neuroscience Masters graduate
Jacinthlyn Sylvia, a Neuroscience Master's graduate from Chennai has worked extensively in deciphering the neurobiology of cognition and motor control in aging. She also has spread-out exposure to Neurosurgery from her Bachelor’s. She is currently involved in active Neuro-Oncology research. She is an upcoming neuroscientist with a fiery passion for writing. Her news cover at Medical Dialogues feature recent discoveries and updates from the healthcare and biomedical research fields. She can be reached at editorial@medicaldialogues.in
Dr Kamal Kant Kohli-MBBS, DTCD- a chest specialist with more than 30 years of practice and a flair for writing clinical articles, Dr Kamal Kant Kohli joined Medical Dialogues as a Chief Editor of Medical News. Besides writing articles, as an editor, he proofreads and verifies all the medical content published on Medical Dialogues including those coming from journals, studies,medical conferences,guidelines etc. Email: drkohli@medicaldialogues.in. Contact no. 011-43720751